Participating Companies

Alligator Bioscience [ATORX:ST] SKr224 MM MCap
The com­pany spe­cial­izes in the de­vel­op­ment of tu­mor-di­rect­ed im­munother­a­pies, in par­tic­u­lar ag­on­is­tic mono- and bis­pe­cif­ic anti­bodies. In im­munother­a­py, the pa­tients´ im­mune sys­tem is ac­ti­vat­ed to cure can­cer. The term tu­mor-di­rect­ed means that the drug is ad­min­is­tered or de­signed such that the phar­ma­co­log­i­cal ef­fect is lo­cal­ized to the tu­mor. [more in­for­ma­tion]
Bavarian Nordic A/S [BVNRY] $3,163 MM MCap
Vaccines for in­fec­tious dis­eas­es and on­col­o­gy. [more in­for­ma­tion]
BerGenBio ASA [BGBIO:OS] NKr1,617 MM MCap
Ber­Gen­Bio is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on de­vel­op­ing a pipe­line of first-in-class se­lec­tive AXL ki­nase in­hibi­tors to treat mul­ti­ple ag­gres­sive can­cers. [more in­for­ma­tion]
Bioarctic AB [BIOA.B:ST] SKr7,930 MM MCap
BioArc­tic is a Swedish re­search in­ten­sive bio­phar­ma com­pany aimed at de­vel­op­ing new treat­ments that ad­dress the caus­es of dis­eas­es that af­fect the Cen­tral Ner­vous Sys­tem. They af­fect the un­der­ly­ing dis­ease pathol­o­gy and can hope­ful­ly stop or sig­ni­f­i­cant­ly de­lay dis­ease pro­gres­sion. This is a large paradigm shift from to­day’s symp­tom-ori­ent­ed ther­a­pies. [more in­for­ma­tion]
Camurus AB [CAMX:ST] SKr9,239 MM MCap
De­vel­op­ing/com­mer­cial­iz­ing in­no­va­tive/long-act­ing medicines for se­vere & chron­ic con­di­tions (e.g. opi­oid de­pen­dence, pain, can­cer & en­docrine di­s­or­ders). Fluid­Crys­tal® drug de­liv­ery tech­nolo­gies for im­proved Q of life, treat­ment out­comes and re­source uti­l­iza­tion. [more in­for­ma­tion]
Forward Pharma A/S [FWP] $48 MM MCap
The Com­pany grant­ed to Bio­gen an ir­re­vo­ca­ble li­cense to all of its IP through the Li­cense Agree­ment and re­ceived from Bio­gen a non-re­fund­able cash fee of $1.25 bil­lion in Fe­bruary 2017, with the re­turn of EUR 917.7 mil­lion to share­hold­ers through a cap­i­tal re­duc­tion in Septem­ber 2017. [more in­for­ma­tion]
Hansa Medical [HMED:ST]
Han­sa Med­i­cal is a bio­phar­ma­ceu­ti­cal com­pany fo­cused on im­muno­mo­d­u­la­to­ry en­zymes for treat­ment and pre­ven­tion of rare and se­vere au­toim­mune con­di­tions and tran­s­plant re­jec­tion. Their cen­tral as­set, can­di­date drug IdeS, is cur­rent­ly in Phase II de­vel­op­ment in kid­ney tran­s­plan­ta­tion. [more in­for­ma­tion]
Immunovia AB [IMMNOV:ST] SKr2,772 MM MCap
Im­munovia’s strat­e­gy is to de­ci­pher the wealth of in­for­ma­tion in blood and trans­late it in­to clin­i­cal­ly use­ful tools to di­ag­nose com­plex dis­eas­es ear­li­er and more ac­cu­rate­ly than pre­vi­ous­ly pos­si­ble. [more in­for­ma­tion]
Medivir AB [MVIR.B:ST] SKr806 MM MCap
De­vel­op­ing MIV-711: a cathepsin K in­hibi­tor in cur­rent Ph 2a study for mod­er­ate knee os­teoarthri­tis with da­ta ex­pect­ed in 3Q 2017; Remeti­no­s­tat: a Ph 3 ready top­i­cal HDAC in­hibi­tor for the treat­ment of ear­ly stage cu­ta­neous T-cell lym­pho­ma (CT­CL); and Biri­na­pant: a Ph 2 ready bi­va­lent SMAC mimet­ic for the treat­ment of solid tu­mors and other on­col­o­gy in­di­ca­tions. [more in­for­ma­tion]
Moberg Pharma [MOB:ST] SKr254 MM MCap
Moberg Phar­ma AB (publ) is a rapid­ly grow­ing Swedish phar­ma­ceu­ti­cal com­pany with OTC sales op­er­a­tions in the U.S. Kerasal Nail®(Emtrix®, Zan­mi­ra®or Nalox™ in cer­tain mar­kets) is a lead­ing OTC treat­ment of nail di­s­or­ders in the U.S. [more in­for­ma­tion]
Nordic Nanovector ASA [NANO:OS]
Fo­cused on de­vel­op­ment of Anti­body-Ra­dionu­clide-Con­ju­gates (ARC). Lead as­set Be­ta­lutin, a nov­el an­ti-CD37 ARC (Luteti­um-177) ra­dioim­munother­a­peu­tic for the treat­ment of Non-Hodgkin Lym­pho­ma, en­ter­ing piv­o­tal Ph 2 PARADIGME trial in 4Q17. Deep pipe­line of ad­di­tio­n­al tar­get­ed ther­a­pies for hae­ma­to­log­i­cal can­cers. [more in­for­ma­tion]
Novo Nordisk A/S [NVO] $247,244 MM MCap
No­vo Nordisk dis­cov­ers and de­vel­ops in­no­va­tive medicines and makes them ac­ces­si­ble to pa­tients through­out the world. The com­pany’s US head­quar­ters are lo­cat­ed in Plains­boro, NJ, and the No­vo Nordisk US busi­ness pres­ence stretch­es from coast to coast -- from an in­sulin man­u­fac­tur­ing plant in North Car­oli­na to the No­vo Nordisk Re­search Cen­ter in Seat­tle, WA. [more in­for­ma­tion]
Nuevolution [NUE:ST] SKr1,605 MM MCap
Scan­di­na­vian bio­phar­ma­ceu­ti­cal com­pany fo­cused on de­vel­op­ing drug treat­ments for hu­man dis­eas­es within on­col­o­gy and chron­ic in­flam­ma­to­ry dis­eas­es. We have set our fo­cus and ob­jec­tives to be: Re­al­iza­tion of ef­fi­ca­cious, safer, tablet based, and low­er cost medicines, for treat­ment of se­vere chron­ic in­flam­ma­to­ry dis­eas­es like e.g. [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr342 MM MCap
Po­ten­tial ap­pro­val for Melflufen (Yga­lo) 1Q21. First in class pep­tide-drug con­ju­gate (PDC) that tar­gets aminopep­ti­das­es and rapid­ly re­leas­es alky­lat­ing agents in­to tu­mor cells. H2H ver­sus Po­m­alyst com­plet­ed en­roll­ment Sep '20. [more in­for­ma­tion]
Orexo AB [ORX:ST] SKr1,111 MM MCap
Orexo is an in­te­grat­ed phar­ma­ceu­ti­cal com­pany with com­mer­cial op­er­a­tions in the Unit­ed States and R&D in Swe­den de­vel­op­ing im­proved treat­ments us­ing pro­pri­e­tary drug de­liv­ery tech­nol­o­gy. The Zub­solv sublin­gual tablet is a nov­el for­mu­la­tion of buprenor­phine and nalox­one us­ing Orexo’s ex­ten­sive knowl­edge in sublin­gual tech­nolo­gies. [more in­for­ma­tion]
Orion Corporation [ORNAV:HI] €5,264 MM MCap
Ori­on is a Fin­nish de­vel­op­er of medicines and di­ag­nos­tic tests - a well-be­ing builder who works glob­al­ly. The core ther­a­py ar­eas of Ori­on's phar­ma­ceu­ti­cal re­search in­clude cen­tral ner­vous sys­tem dis­eas­es, can­cer dis­eas­es and re­s­pi­ra­to­ry dis­eas­es that Ori­on de­vel­ops in­haled Easy­haler® pul­mo­nary drugs. [more in­for­ma­tion]
Orphazyme [ORPHA:CO] DKr888 MM MCap
The com­pa­nies de­vel­op­ment pro­grams tar­get dis­eas­es that are as­so­ci­at­ed with aber­ra­tions in the pro­tein home­os­ta­sis, such as those char­ac­ter­ized by loss-of-func­tion of one or more pro­teins or the for­ma­tion of pro­tein-con­tain­ing ag­gre­gates. [more in­for­ma­tion]
Photocure ASA [PHCUF] $330 MM MCap
Hexvix®/Cysview® with pro­pri­e­tary pho­to­dy­nam­ic tech­nol­o­gy is on mar­ket for the di­ag­no­sis and ma­n­age­ment of blad­der can­cer. Com­mer­cial­ized us­ing Co’s spe­cial­ist sales­force in Nordic and US; part­nered in other re­gions. Re­cent­ly re­port­ed pos­i­tive Ph 3 da­ta for Hexvix/Cysview w/ blue-light flo­res­cence cys­tos­copy in surveil­lance sett­ing; [more in­for­ma­tion]
PledPharma AB [PLED:ST]
The com­pany’s most ad­vanced pro­ject Ple­dOx® re­duces nerve da­m­age as­so­ci­at­ed with che­mother­a­py. The drug can­di­date Al­a­dote® is de­vel­oped to re­duce the risk of acute liv­er fail­ure as­so­ci­at­ed with ac­e­taminophen poi­son­ing. [more in­for­ma­tion]
Q-LINEA
The prod­uct clos­est to mar­ket is AS­Tar™, a ful­ly au­to­mat­ed in­stru­ment for antibi­ot­ic sus­cepti­bil­i­ty test­ing (AST), giv­ing a sus­cepti­bil­i­ty pro­file within six hours di­rect­ly from a pos­i­tive blood cul­ture. The next prod­uct in de­vel­op­ment is ASTrID®, a plat­form for iden­ti­fi­ca­tion (ID) and AST of patho­gens di­rect­ly from blood – with­out the need for tra­di­tio­n­al blood cul­tur­ing. [more in­for­ma­tion]
Sobi - Swedish Orphan Biovitrum [SOBI:ST] SKr68,975 MM MCap
So­bi re­search and prod­uct port­fo­lio is pri­mar­i­ly fo­cused on hae­mophilia, in­flam­ma­tion and ge­net­ic and metabolic dis­eas­es. They mar­ket and make avai­l­able across Eu­rope, the Mid­dle East, North Afri­ca and Rus­sia a port­fo­lio of spe­cial­ty and rare dis­ease prod­ucts for part­n­er com­pa­nies. [more in­for­ma­tion]
Targovax [TRVX]
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]
Wilson Therapeutics [WTX:ST] SKr6,493 MM MCap
Fo­cused on rare dis­eas­es. Ex­pects to ad­vance WTX101, a nov­el first-in-class cop­per-pro­tein-bind­ing agent for treat­ment of Wil­son Dis­ease in­to piv­o­tal Phase 3 FO­CuS study in ear­ly 2018; grant­ed OD in US/EU and FDA fast track sta­tus. WTX101 al­so grant­ed OD for ALS in US; plan to in­vesti­gate in SOD-1 mu­tat­ed ALS. [more in­for­ma­tion]
XBrane Biopharma [XBRANE:ST] SKr3,160 MM MCap
The seg­ment has a high en­try bar­ri­er, driv­en by high pro­duc­tion com­plex­i­ty and the need of spe­cif­ic Know-How. Xbrane cur­rent­ly pos­sess its own ex­per­tise within pro­duc­tion of com­plex gener­ics with slow re­lease for­mu­la­tion and unique tech­nolo­gies for pro­duc­ing pro­teins ef­fi­cient­ly. [more in­for­ma­tion]
Zealand Pharma A/S [ZEAL] $1,376 MM MCap
Spe­cial­iz­ing in nov­el pep­tide drug de­vel­op­ment in car­dio-metabolic dis­eas­es. Part­nered w/ SNY on lead com­pound, lixise­natide, for T2 di­a­betes. Ad­dt'l part­n­ers - Boehringer In­gel­heim, LLY, Helsinn & AB­BV. [more in­for­ma­tion]